Arkolith/Insider Trading/RAPH/Form 4

Louria Hayon Igal

Chief Technology Officer, DirectorRaphael Pharmaceutical Inc. (RAPH) · full profile →Form 4 · filed Mar 13, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
1
0 non-derivative · 1 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 5, 2022Grant(A)999K—$0990K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001213900-23-019554) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML